Skip to main content

Table 1 Properties of KPC-positive clinical isolates and transformant strains. Isolates were collected from 29 patients in the time period January 2009-June 2010

From: KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December 2011: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units

Sample ID Hospital unit carbapenemase β-lactamase molecular typing MIC (mg/L)
   KPC VIM TEM SHV CTX OXA MLST PFGE ERIC IPM MER CTX CAZ FEP SXT GEN AMK TGC
13 SAH-ICU 2 1 1 12 nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 32 2
20 SAH-ICU 2 1 1 12 nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 2
39 SAH-ICU 2 nd 1 nd nd 9 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 40 ≤1 ≤2 2
40 SAH-ICU 2 nd 1 nd nd 9 147 A a ≥16 ≥16 32 16 32 40 ≤1 ≤2 2
Top10-41            8, 2 2, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
42 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 32 40 ≤1 ≤2 2
46 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
49 SAH-ICU 2 1 nd nd nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
65 SAH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 8 ≥64 8 ≥320 2 ≥64 2
68 SAH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 32 ≥64 8 ≥320 4 ≥64 2
69 SAH-ICU 2 nd 1 12 nd 9 147 A a ≥16 ≥16 32 16 ≥64 40 ≤1 ≤2 2
Top10-69            8, 3 1, 1 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
74 SAH-ICU 2 nd nd nd nd nd 147 A a ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 2
35 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 8 2
Top10-35            8, 2 1, 0.75 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
44 TH-ICU 3 nd 1 nd nd 9 258 B b 8 8 8 ≥64 16 ≥320 ≥16 16 2
Top10-44            8, 1.5 1, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
45 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 2 ≥64 ≥64 16 ≥320 ≥16 8 2
48 TH-ICU 3 nd nd nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 8 2
53 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 16 ≥320 ≥16 ≥64 2
Top10-53            8, 2 2, 0.38 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
63 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 ≥64 ≥64 32 ≥320 ≥16 16 2
71 TH-ICU 3 nd 1 11 nd 9 258 B b 4 2 16 ≥64 8 ≥320 ≥16 8 2
72 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 4 16 ≥64 8 ≥320 4 ≥64 4
12 TH-SU   nd nd nd nd nd 527 C c ≥16 ≤0.25 ≤1 ≤1 ≤1 ≥320 ≤1 4 2
Top10-12            8, 2 2, 0.5 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
14 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 8 8 ≥64 8 ≥320 2 ≥64 4
19 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 2 8 ≥64 ≥64 ≥320 2 ≥64 2
8 TH-MU 3 nd 1 11 nd 9 258 B b ≥16 2 8 ≥64 16 ≥320 4 ≥64 2
17 TH-MU 3 nd 1 11 nd 9 258 B b ≥16 4 8 ≥64 8 ≥320 4 ≥64 4
18 TH-MU 3 nd 1 11 nd 9 258 B b 4 2 16 ≥64 8 ≥320 4 ≥64 4
4 TH-LTCU 3 nd 1 11 nd 9 258 B b 4 2 8 ≥64 8 ≥320 4 ≥64 2
7 TH-LTCU 3 nd 1 11 15 9 37 D b ≥4 2 ≥64 ≥64 ≥64 ≥320 8 ≤2 2
Top10-7            8, 3 2, 1 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
21 TH-ICU 3 nd 1 11 nd 9 258 B b ≥16 ≥16 ≥64 ≥64 ≥64 ≥320 4 ≥64 1
64 TH-ICU 3 nd 1 nd nd 9 258 B b ≥16 8 8 ≥64 16 ≥320 ≥16 16 2
Top10-64            8, 2 1, 0.38 ≥64 4 2 ≤20 ≤1 ≤2 ≤0.5
Top10            ≤1, 0.25 ≤0.25, 0.32 ≤1 ≤1 ≤1 ≤20 ≤1 ≤2 ≤0.5
  1. IPM = imipenem; MER = meropenem; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; SXT = sulfamethoxazole-trimethoprim; GEN = gentamicin; AMK = amikacin; TGC = tigecycline. Transformed E. coli strains are indicated as Top10 and the number corresponding to the clinical sample from which the plasmid was obtained.
  2. In transformed Top10 strains, MIC values of imipenem and meropenem were obtained by Vitek (first MIC value) and E-test (second MIC value in italics).